Achieving Faster Bleeding Disorder Treatment in the Emergency Department: A Quality Improvement Initiative Authors: Kristen Adams, Megan Caskey, Lindsey Neill, Daryl Moczygemba, Yingchao Yuan, Sheryl Yanger, Erin Munns, Jennifer Heineman, Arun Gurunathan Published: 2026 ABSTRACT Introduction:People with bleeding disorders (PwBD) often rely on the emergency department (ED) for clotting factor concentrate (CFC) administration for apparent or suspected bleeding. Timely CFC administration reduces complications but is challenging due to high ED patient volumes and uncertainty about the treatment type, dose, and timing (especially in the pediatric population). Our project aimed to improve the time to CFC for PwBD presenting to the ED with bleeding concerns, with an initial SMART (specific, measurable, achievable, relevant, and time-bound) aim of decreasing the median time from 129 to 99 minutes within 6 months.Methods:Our interventions included educational initiatives, personalized management cards, improved hematology-to-ED communication, and the development of an evidence-based algorithm and guideline.Results:We exceeded our SMART aim, reducing the median time to CFC to82 minutes during the 6 months, and since then we have further improved treatment times, with a median time to CFC of 61 minutes since project initiation (53% reduction from baseline) and a median time to CFC of 41 minutes during the most recent 6 months of data collection (68% reduction from baseline).Conclusions:Our results highlight the successful and sustained application of quality improvement methodologies to improve CFC administration time in PwBD. INTRODUCTION Emergency departments (EDs) are often the initial point of care for people with bleeding disorders (PwBDs)—including those with hemophilia or other clotting deficiencies—who are experiencing acute bleeding episodes or injuries.1,2 Many PwBD require clotting factor concentrate (CFC) because they are at risk for severe, potentially life-threatening bleeding.3–5 Delays in appropriate CFC administration can markedly affect morbidity and mortality. The National Bleeding Disorders Foundation recommends high-acuity triage and CFC administration within 60 minutes of ED arrival, without delaying infusion due to laboratory or imaging results, even if the final evaluation does not show that any bleeding is ultimately identified.6 CFC administration delays are common in busy EDs.7,8 Contributing factors include inappropriate triage, uncertainty about CFC type or dose, especially in pediatrics, where dosing varies by age and weight, and waiting for laboratory/imaging results.9,10 We identified these pitfalls at our institution and tailored interventions accordingly. This article describes an interdisciplinary quality improvement (QI) project aimed at reducing CFC administration times among PwBD. METHODS We submitted the study protocol to the University of Texas institutional review board, which determined that it did not involve human subjects and therefore did not require institutional review board approval or oversight. Setting Our Hemophilia Treatment Center is a pediatric, hospital-based quaternary care clinic that follows more than 400 patients with bleeding disorders from birth to around 25 years of age. When our established patients are experiencing acute bleeding episodes or injuries, and it is not feasible or appropriate for them to be seen in the clinic, they are instructed to go to the ED. Our hospital is an urban level 1 trauma center with a pediatric ED that averages more than 60,000 patient visits per year. The ED has 24-hour access to pharmacists (though there is not a pharmacy within the ED itself) and emergency imaging facilities. The ED/inpatient electronic medical record (EMR) is FirstNet software provided by Cerner (Kansas City, MO). The outpatient EMR is Athena One, provided by Athenahealth (Boston, MA). Upon arrival, registration and nursing staff briefly check in patients. If there is a wait, a triage nurse obtains vital signs and history to determine the triage level. An advanced practice provider or physician in triage may order CFC; otherwise, the triage nurse messages an ED provider to place a CFC order. If there is no wait, the patient is roomed in the ED, and the bedside nurse performs triage. The ED provider contacts the on-call hematology attending via the Voalte Me Health Insurance Portability and Accountability Act (HIPAA)-compliant text system provided by Baxter (Deerfield, IL). If no reply is received within 10–20 minutes, the hematologist is contacted by phone. For patients requiring CFC from the hospital supply, the ED provider places an order in the EMR, and the medication is then brought to the bedside by pharmacy staff. For patients using a home supply of CFC, the provider places a nonformulary home medication order; an ED technician delivers the medication to the pharmacy; the pharmacist checks and relabels it; and the pharmacy staff then brings it to the bedside. Aims Baseline data showed a preproject median of 129 minutes from ED arrival to CFC administration. Our global aim was to shorten the time to appropriate treatment for PwBD seeking emergency care. The aim was to decrease the median time to CFC (from ED arrival to CFC administration) by 30 minutes (from 129 to 99 min) for PwBD presenting with bleeding concerns from October 1, 2023, to March 31, 2024. We also aimed to further reduce the median time to CFC, increase the proportion of patients treated within 60 minutes, and improve the percentage of patients triaged at the appropriate level. At our center, a PwBD with bleeding should be triaged as Emergency Severity Index (ESI) level 1 or 2.11 Interventions We established a multidisciplinary QI team consisting of a hematology physician and nurse practitioner, a QI nurse, a data analyst, ED physicians, and an ED nurse. Initial process improvement work began with conducting a manual review of the health records of the PwBD who received CFC in our ED. The Institute for Healthcare Improvement Model for Improvement framework guided this project. The multidisciplinary group designed a fishbone diagram (Fig. 1) and a key driver diagram (Fig. 2) to better understand the issues and to focus the development of our interventions. We identified that education for ED staff, PwBD, and their families was a significant opportunity for improvement that could be addressed with relative ease and at low cost, so this was our area of focus during the 6-month SMART aim timeframe of the QI project. Cause-and-effect “fishbone” diagram detailing issues that likely contribute to delays in administration of clotting factor concentrate therapy. IV, Intravenous; RN, Registered Nurse. Key driver diagram showing the global goal, SMART aim, key drivers, and interventions. Initial Interventions during the 6-month SMART Aim Period Educational sessions for ED staff: In October 2023, we educated ED providers on key principles of managing the care of PwBD, including the selection of CFC type/dose and the early administration before laboratory testing/imaging. In November 2023, we educated ED nurses on nursing considerations, including appropriate triage. Both sessions included discussions about barriers and suggestions for care delivery. Educational sessions for ED staff: In October 2023, we educated ED providers on key principles of managing the care of PwBD, including the selection of CFC type/dose and the early administration before laboratory testing/imaging. In November 2023, we educated ED nurses on nursing considerations, including appropriate triage. Both sessions included discussions about barriers and suggestions for care delivery. Individualized bleeding disorder management cards: Starting in December 2023, we created laminated cards to help PwBD communicate key details to ED staff, including diagnosis, hematology contact information, prompt CFC administration principles, and individualized treatment recommendations (Fig. 3). We distributed cards during clinic visits and taught patients/families how to use them during ED visits. Individualized bleeding disorder management cards: Starting in December 2023, we created laminated cards to help PwBD communicate key details to ED staff, including diagnosis, hematology contact information, prompt CFC administration principles, and individualized treatment recommendations (Fig. 3). We distributed cards during clinic visits and taught patients/families how to use them during ED visits. Template for personalized patient bleeding disorder management card. Front (A) and back (B). ASAP, as soon as possible. Monthly, our QI group reviewed the preceding month’s time-to-CFC data. For prolonged times, we held discussions with relevant ED staff to identify root causes and determine whether targeted reminders (eg, reeducation for triage staff in February 2024 following patient delays due to triage errors) or new interventions were needed. We used Plan-Do-Study-Act cycles to test and refine improvement strategies throughout the project (during the SMART aim period and beyond). We adopted and integrated effective interventions into our practice standards as the project progressed. During and after the SMART aim period, it was clear that interventions to improve education, communication, and resources would be beneficial. Subsequent Interventions Optimizing education: After ED leadership staff feedback and increased CFC delivery delays in the summer of 2024, we held formal education sessions annually with ED staff in July/August, when new staff/trainees are onboarded. ED staff also added bleeding disorder care information to the front check-in desk in the ED, where the triage nurse and provider are located, and to the shift huddle board. Optimizing education: After ED leadership staff feedback and increased CFC delivery delays in the summer of 2024, we held formal education sessions annually with ED staff in July/August, when new staff/trainees are onboarded. ED staff also added bleeding disorder care information to the front check-in desk in the ED, where the triage nurse and provider are located, and to the shift huddle board. Enhancing CFC dose communication with the ED: Beginning in June 2024, hematology triage staff specified the exact CFC product and dose during prearrival calls when directing patients to the ED. We embedded a triage prompt tool in the EMR and standardized CFC dosing documentation using an “Acute Bleeding Treatment Plan” template from outpatient clinic notes, individualized for each patient. Enhancing CFC dose communication with the ED: Beginning in June 2024, hematology triage staff specified the exact CFC product and dose during prearrival calls when directing patients to the ED. We embedded a triage prompt tool in the EMR and standardized CFC dosing documentation using an “Acute Bleeding Treatment Plan” template from outpatient clinic notes, individualized for each patient. Evidence-based algorithm and guideline: As a joint hematology/ED collaboration, we created an algorithm for CFC administration for patients with hemophilia A and B (the most common bleeding disorders requiring CFC) presenting with a bleed, injury, or pain (Fig. 4). This algorithm is readily available to ED staff via the hospital webpage. It is intended to aid/expedite decision-making; highlight the key features of proper, timely care; and provide logistical clarity. We also created a guideline document that includes background information and a summary of evidence supporting the algorithm. Evidence-based algorithm and guideline: As a joint hematology/ED collaboration, we created an algorithm for CFC administration for patients with hemophilia A and B (the most common bleeding disorders requiring CFC) presenting with a bleed, injury, or pain (Fig. 4). This algorithm is readily available to ED staff via the hospital webpage. It is intended to aid/expedite decision-making; highlight the key features of proper, timely care; and provide logistical clarity. We also created a guideline document that includes background information and a summary of evidence supporting the algorithm. Additional patient/family education: With a community bleeding disorder organization, we created “Navigating the Emergency Room: Tips for Success,” an interactive presentation delivered at 2 community events. It reinforced the ED-related teaching points, included patient/family Q&A, and generated feedback on ED barriers and opportunities for improvement. Additional patient/family education: With a community bleeding disorder organization, we created “Navigating the Emergency Room: Tips for Success,” an interactive presentation delivered at 2 community events. It reinforced the ED-related teaching points, included patient/family Q&A, and generated feedback on ED barriers and opportunities for improvement. Evidence-based algorithm to help guide and expedite care of patients with hemophilia in the ED. The numbers “1” through “4” in black circles correspond with the numbers in the bottom right corner of the text boxes that provide additional clarifying information. CT, Computed Tomography; DCMC, dell children’s medical center; GI, Gastrointestinal; MVC, motor vehicle collision; TNF, template non formulary. Measure/Outcomes The primary outcome was the median time from ED presentation to CFC administration. A secondary outcome was the percentage of patients correctly triaged as level 1 or 2. At our institution, triage nurses assign an ESI number from 1 to 5 (1 representing the highest acuity and 5 the lowest) to all patients presenting to the ED. ED staff prioritize patients with a lower assigned triage number to ensure prompt initiation of interventions and evaluation by an ED provider. Data Collection and Analysis Data included patient arrival and triage time/level; CFC order, dispensing, and sourcing; and administration times. We included patients with hemophilia and other bleeding disorders who presented to our ED with injury, a bleeding episode, or significant pain and received CFC, including von Willebrand disease, other factor deficiencies, and platelet dysfunction disorders. We excluded PwBD who intentionally received CFC later due to home CFC administration or perioperative planning. We developed monthly annotated control charts with median lines and calculated means and SDs. RESULTS We collected data on 107 total encounters in the ED between October 2021 and September 2025. The preproject group and the project group (including both the SMART aim period and the post-SMART aim period) contained 41 and 66 encounters, respectively. Demographics, including sex, age, and bleeding disorder type/severity, were similar between the 2 groups (Table 1). Table 1.DemographicsPatient CharacteristicsPreproject Group, n = 41Project Group, n = 66Sex, n (%) Male39 (95.1)62 (93.9) Female2 (4.9)4 (6.1)Median age, y4.395.61Type of bleeding disorder, n Hemophilia A1848 Hemophilia B1411 von Willebrand disease33 Glanzmann thrombasthenia12 Hemophilia A and von Willebrand disease52Hemophilia severity, n Hemophilia A Severe1025 Moderate111 Mild710 Ambiguous severity02 Hemophilia B Severe76 Moderate75 Mild00 Hemophilia A and von Willebrand disease Severe31 Moderate21 Demographics In the preproject period, the median time to CFC was 129 minutes, with a mean of 167 minutes and an SD of 99 minutes. During the 6-month SMART aim period from October 2023 to March 2024, the median time decreased to 82 (mean 107, SD 65) minutes. In the overall project period from October 2023 to September 2025, the median time to CFC was even lower at 61 (mean 73, SD 46) minutes. In the post-SMART aim period (April 2024–September 2025), the median time to CFC was 56 (mean 61, SD 30) minutes (Fig. 5). For the last 6 months of the data collection period (April 2025–September 2025, 20 encounters), the median time to CFC was 41 (mean 47, SD 18) minutes, which was a 68% decrease from the preproject baseline, with 18 out of 20 (90%) patients receiving CFC within 60 minutes. Regarding our secondary outcome measure, the percentage of patients triaged appropriately (ESI level 1 or 2) increased from 80% to 94% between the preproject and project periods. Median time to clotting factor concentrate therapy for each patient encounter, with October 1, 2021–September 30, 2023, representing preproject baseline; October 1, 2023–March 31, 2024, representing SMART aim period; and April 1, 2024–September 30, 2025, representing post-SMART aim period. The centerline shifts to show the median value for each of these 3 time periods. Dates and details of interventions are listed. CFC, clotting factor concentrate; LCL, lower control limit; NBDF, National Bleeding Disorders Foundation; UCL, upper control limit. DISCUSSION Emergency care has been expedited for conditions such as asthma and sepsis, and bleeding disorders warrant similar urgency.12,13 Prompt CFC administration is essential for patients with possible bleeding, yet meeting the National Bleeding Disorders Foundation 60-minute recommendation is difficult amid high ED volumes and long wait times. Improper triage, limited ED familiarity with bleeding disorder management, and patient/family education gaps can worsen delays.14,15 Our QI initiative addressed these barriers through multidisciplinary teamwork, staff/patient/family education, and clinical tools and reminders selected for low cost, feasibility, and generalizability. After implementation of the initial interventions, the median time to CFC administration decreased substantially, with a further decline in time to CFC after the continuation and optimization of the initial interventions and the implementation of new initiatives. Additionally, these interventions increased the percentage of patients who were triaged appropriately, enabling more timely evaluation by ED providers and contributing to the prompt administration of CFC. Initial interventions centered on in-person education for ED providers and nurses and personalized management cards for PwBD/families. The cards both communicate key, patient-specific management information to the ED for each PwBD and serve as a tool for the patient to communicate with ED staff and reinforce family education. This combined clinical staff and patient/family approach was essential to the early success. Review of the data showed that the median time between ED arrival and CFC order placement in the EMR accounted for a significant portion of the delay; education reduced this interval from 81 minutes preproject to 28 minutes after initial interventions. Feedback from ED staff and patients/families identified additional barriers and helped reduce this interval to 17 minutes in the post-SMART aim period. The monthly multidisciplinary QI meetings, which reviewed CFC timing data and discussed overall feedback/suggestions, were critical to the project’s success. When we required clarification of the reason(s) for a particular delay, reaching out to the treating ED provider and/or nurse was invaluable. These and other discussions facilitated the development of additional adjustments and interventions not only to sustain but also to further improve the time to CFC administration. Post-SMART aim interventions optimized education and improved workflow through enhanced communication and resources. A summer 2024 spike in time to CFC seemed related to new trainees/staff, prompting annual summer ED education sessions held during already-scheduled mandatory meetings for attendings/fellows and/or nurses, with resident education supported by supervising physicians. We also optimized family education by leveraging local opportunities to reinforce the ED-related teaching points discussed during clinic visits. We enhanced clinical workflow by publishing an evidence-based algorithm and guideline and streamlining how ED providers access the specific information needed to manage PwBD. Increasing the ease with which providers could access the necessary CFC information contributed to the timeliness of CFC administration. In an ever-changing landscape of bleeding disorder treatments, our model allows for continual updates to align with the latest evidence-based guidelines. We reviewed balancing metrics and did not note any adverse changes, including no increase in length of stay, no pharmacy errors, and no ED staff frustration or complaints. There were no instances of “overtreatment”-induced thrombosis or infusion reaction. Reliability and sustainability of the QI project are key considerations. In the levels-of-reliability framework, level 1 (80%–90% reliability) interventions included various educational sessions, personalized bleeding-management cards, and standardized treatment-plan documentation. Level 2 (~95% reliability) interventions included creating the ED algorithm and beginning to build hard-wired systems, such as triage prompts. Level 3 (~99% reliability) intervention included making the system highly visible by posting key pearls and resources on bleeding disorder management and care on the ED huddle board for staff to review each shift.16 We intend to continue reducing time to CFC through future PDSA cycles, emphasizing level 2 and 3 reliability strategies and hard-wired systems. In-progress work includes personalized high-alert plans accessible in the ED EMR and expansion of triage prompts for ED intake and triage staff. Allowing broader administration of home CFCs in the ED may further reduce barriers for all eligible patients. We also continue to address triage accuracy through group education, a multidisciplinary review of inaccurate triage designations, and near-real-time targeted feedback. LIMITATIONS We conducted this study at an academic, urban, pediatric, level 1 trauma center, which may affect the generalizability of our findings. Additionally, we did not obtain other outcome data, such as patient, family, and ED staff satisfaction or objective measures of knowledge gain. An important limitation in designing interventions was our institution’s EMRs. We use separate inpatient and outpatient EMRs, and many ED providers do not have access to outpatient records. This fact impeded our ability to put personalized patient factor information in a clear “one-stop” area that both ED and outpatient staff could quickly/reliably access. One more limitation is that we designed our data capture to focus on PwBD who received CFC in the ED, and so may have missed any PwBD for whom delay led to leaving before CFC treatment. CONCLUSIONS Expeditious CFC treatment in the ED is an important but challenging goal. A multimodal approach with multidisciplinary communication and feedback was crucial to improvement. Our improvement strategies focused on education, improving and streamlining communication, and developing high-yield clinical tools and resources to guide and expedite workflow. This QI project met its initial time-to-CFC goal, and ongoing efforts further accelerated CFC administration, with recent times down 68% from the preproject baseline. Our results show that improvement can be seen within months, and a dramatic reduction in time to CFC is feasible in less than 2 years. Additionally, we increased the proportion of patients who were appropriately triaged. This project illustrates the effective use of the Institute for Healthcare Improvement Model for Improvement to reduce CFC administration times in an ED setting. Our findings also highlight successful improvements during the 2-year period, indicating a sustainable change. Future investigations should explore the implementation of similar interventions across diverse ED settings, including academic and community EDs, as well as urban and rural areas. We believe that our study offers a practical approach that can benefit other EDs aiming to achieve the important quality and patient safety metric of timely CFC administration. DISCLOSURES Dr. Gurunathan received an honorarium in October 2024 from Sanofi Pharmaceuticals for participation in an advisory board meeting for a hemophilia CFC medication (this medication is not discussed in this article). The other authors have no financial interest to declare in relation to the content of this article.